Alex Azar's drug pricing agenda should he become Health and Human Services Secretary includes ensuring clearer times for generic entry, as well as removing barriers posed by Risk Evaluation and Mitigation Strategies (REMS).
During a hearing Nov
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?